The FDA has approved dupilumab (Dupixent) for the treatment of allergic fungal rhinosinusitis, a rare form of chronic sinus inflammation driven by hypersensitivity to fungal organisms in the sinuses, in...
Stapokibart, a novel anti–IL-4Rα monoclonal antibody, significantly reduced nasal polyp size and congestion in patients with severe chronic rhinosinusitis with nasal polyps, with improvements evident as...
According to a post hoc analysis, in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, tezepelumab improved nasal and asthma symptoms across multiple...
The researchers aimed to differentiate the demographic characteristics of US patients with chronic rhinosinusitis and those of the general US population, as well as to differentiate the demographic...
The nomogram was developed with data from 96 patients who had surgery earlier in the study period and was validated with data from 62 patients who had surgery later in the period, after the nomogram was...
The double-blind, phase 3 SYNAPSE trial included 407 patients from 93 sites in 11 countries. Participants were adults with recurrent, refractory, severe, bilateral nasal polyp symptoms who, despite...
In a recent study, researchers examined how routine tissue sampling following sinus surgery may be useful for the diagnosis and treatment of bilateral nasal polyposis.
This roundup discusses recent research on the pathogenesis and prognoses of chronic rhinosinusitis with nasal polyps, chronic rhinosinusitis without nasal polyps, and aspirin-exacerbated respiratory...
The FDA has approved a nasal antihistamine for nonprescription use in the treatment of seasonal and perennial allergic rhinitis in individuals aged 6 years and older.
In response to new FDA-approved treatments for chronic rhinosinusitis with nose polyps, a group of experts has developed a stepwise treatment paradigm for patients with the condition.
